

Reference number(s) 6120-A

Specialty Guideline Management Elrexfio

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Elrexfio	elranatamab-bcmm

Indications

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy

FDA-approved Indications

Elrexfio is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

All other indications are considered experimental/investigational and not medically necessary.

Coverage Criteria

Multiple Myeloma

Authorization of 12 months may be granted for treatment of relapsed or refractory multiple myeloma in members who have received at least 4 prior therapies, including at least one drug from each of the

Elrexfio SGM 6120-A P2024_R.docx

© 2024 CVS Caremark. All rights reserved

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

Reference number(s) 6120-A

following categories:

- Anti-CD38 monoclonal antibody (e.g., daratumumab, isatuximab)
- Proteasome inhibitor (e.g., bortezomib, ixazomib, carfilzomib)
- Immunomodulatory agent (e.g., lenalidomide, pomalidomide, thalidomide)

Continuation of Therapy

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization for an indication listed in the coverage criteria when there is no evidence of unacceptable toxicity or disease progression while on the current regimen.

References

1. Elrexfio [package insert]. New York, NY: Pfizer Inc.; August 2023.